Hyperpolarized 129 Xenon Gas

Phase 2

Hyperpolarized 129 Xenon Gas is one of 33 therapeutic programs targeting Interstitial Lung Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Interstitial Lung DiseaseNot yet recruiting

Interstitial Lung DiseasePhase 2

Not yet recruiting

Competition

Competitive Landscape

38 competitors in Interstitial Lung Disease

#DrugCompanyPhaseTrials

Rituxan

Roche

Approved

5 2

Tracleer

Johnson & Johnson

Approved

3 3

Trexall

Jazz Pharmaceuticals

Approved

2 4

Medrol

Pfizer

Approved

2 5

Esbriet

LLegacy Health System

Approved

5 6

Cytoxan

BBaxter Healthcare Corporation

Approved

3 7

Actemra

CCelltrion

Approved

2 8

Cellcept

Roche

Phase 3

4 9

Imuran

LLegacy Health System

Ofev

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Not yet recruiting

Interstitial Lung Disease

NCT07821398

Clinical

Trials by Indication[1]

Interstitial Lung Disease1 trial

Harmonized Hyperpolarized 129Xe MRI for Noninvasive Assessment of Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis (ILD-PH/SSc)

Not yet recruiting·BBastiaan Driehuys·Phase 2·NCT07821398·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hyperpolarized 129 Xenon Gas. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Hyperpolarized 129 Xenon Gas. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Bastiaan Driehuys company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: BBastiaan Driehuys

Hyperpolarized 129 Xenon Gas

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Interstitial Lung Disease1 trial

References

Drug Info

Quick Facts

Related News